STRATA Skin Sciences, Inc. (SSKN)
$
2.43
-0.06 (-2.47%)
Key metrics
Financial statements
Free cash flow per share
-0.1601
Market cap
12.1 Million
Price to sales ratio
0.3598
Debt to equity
0.4369
Current ratio
1.0487
Income quality
-0.0483
Average inventory
2.5 Million
ROE
-1.3822
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
STRATA Skin Sciences, Inc. operates as a medical technology company specializing in the development, commercialization, and marketing of products designed to treat various dermatologic conditions worldwide. The company serves a diverse market, with operations spanning the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It conducts its business through two main segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. STRATA's product line features advanced equipment such as XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are effective in managing conditions like psoriasis, vitiligo, and acne. The gross profit stands at $19,081,000.00 highlighting the company's profitability from core operations. Furthermore, the company reported an income before tax of -$10,256,000.00 showcasing its pre-tax profitability. Reflecting its focused niche market strategy, the company achieved a revenue of $33,562,000.00. Meanwhile, the cost of revenue for the company is $14,481,000.00 showcasing its production and operational expenses. The weighted average number of shares outstanding is 3,807,186.00 highlighting the company's shareholder base. In the financial landscape, STRATA Skin Sciences has positioned itself as an affordable option for investors, with the stock priced at $2.49 making it suitable for budget-conscious investors. However, it's worth noting that the stock has a low average trading volume of 7,873.00 indicating lower market activity. With a market capitalization of $10,135,919.00 the company is classified as a small-cap player, reflecting its size and potential for growth within the industry. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth, which aligns well with the evolving needs of dermatological treatment and technology advancements.
Is STRATA Skin Sciences, Inc. (SSKN) a good investment?
Investing in STRATA Skin Sciences, Inc. (SSKN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is STRATA Skin Sciences, Inc. (SSKN)'s stock forecast?
Analysts predict STRATA Skin Sciences, Inc. stock to fluctuate between $2.10 (low) and $4.10 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is STRATA Skin Sciences, Inc.'s market capitalization?
As of 2025-05-30, STRATA Skin Sciences, Inc.'s market cap is $10,135,919, based on 4,171,160 outstanding shares.
How does STRATA Skin Sciences, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., STRATA Skin Sciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy STRATA Skin Sciences, Inc. (SSKN) stock?
To buy STRATA Skin Sciences, Inc. (SSKN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SSKN. Place an order (Market, Limit, etc.).
What is the best time to invest in STRATA Skin Sciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has STRATA Skin Sciences, Inc. stock ever split?
STRATA Skin Sciences, Inc.'s last stock split was 1:10 on 2024-06-07.
How did STRATA Skin Sciences, Inc. perform in the last earnings report?
Revenue: $33,562,000 | EPS: -$2.65 | Growth: -14.52%.
Where can I find STRATA Skin Sciences, Inc.'s investor relations reports?
Visit https://www.strataskinsciences.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for STRATA Skin Sciences, Inc.?
You can explore historical data from here
What is the all-time high and low for STRATA Skin Sciences, Inc. stock?
All-time high: $28.40 (2021-03-17) | All-time low: $2.10 (2025-05-06).
What are the key trends affecting STRATA Skin Sciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
17 days ago
STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Jules Abraham - CORE IR Dolev Rafaeli - Chief Executive Officer John Gillings - VP of Finance Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Jeremy Pearlman - Maxim Group Operator Good afternoon, and welcome to the STRATA Skin Sciences First Quarter 2025 Financial Results Conference Call. All participants will be in a listen-only mode.
globenewswire.com
17 days ago
HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update.
globenewswire.com
24 days ago
HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will participate in the D. Boral Capital Inaugural Global Conference. The conference is being held on May 14, 2025, at The Plaza Hotel, 768 Fifth Avenue, New York, NY 10019.
globenewswire.com
25 days ago
HORSHAM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2025 financial results on Wednesday, May 14, 2025 after the market close.
seekingalpha.com
2 months ago
Start Time: 16:30 January 1, 0000 5:00 PM ET STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q4 2024 Earnings Conference Call March 27, 2025, 16:30 PM ET Company Participants Dolev Rafaeli - CEO John Gillings - VP of Finance Louie Toma - CORE IR Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Jeremy Pearlman - Maxim Group Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the STRATA Skin Sciences, Inc. Fourth Quarter and Year End 2024 Financial Results and Corporate Update Conference Call.
globenewswire.com
2 months ago
HORSHAM, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter and year ended December 31, 2024, and provides a corporate update.
globenewswire.com
2 months ago
HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close.
globenewswire.com
2 months ago
HORSHAM, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the results of a newly published study in Japan that further validates the technological advantages of high repetition rate, high dose, coherent collimated narrow band Excimer Laser technology over other sources of UVB light that are less accurate, lack the repetition rate and/or fluence capabilities of an Excimer Light for treating Vitiligo, Psoriasis, Alopecia Areata and Atopic Dermatitis. The study, titled “Excimer Laser Penetrates Deeper into Hair Follicles and Activates More Melanocyte Lineage Cells than Excimer Light,” authored by distinguished researchers from the Nippon Medical School and published in the peer reviewed Journal of Nippon Medical School, demonstrates that despite the two devices producing same 308-nm wavelength, the distinct technological characteristics between two devices can have significant impact on the clinical outcomes. Notably, the excimer laser exhibits laser properties (monochromatic coherent light) and unique device specifications (a high frequency of 400 Hz and a remarkably high irradiance that leads to cellular differences such as deeper penetration, greater activation of melanocyte lineage cells (melanocyte stem cells (McSCs) and melanoblasts) resulting in superior clinical outcomes in terms of greater pigmentation and fewer epidermal side effects relative to excimer light. This study provides further scientific evidence that the modality generating UVB light has significant impact on the clinical outcomes of a device.
zacks.com
5 months ago
Strata Skin Sciences (SSKN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
globenewswire.com
6 months ago
HORSHAM, Pa., Dec. 05, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that President and Chief Executive Officer Dr. Dolev Rafaeli will participate in the Benchmark Company 13th Annual Discovery Investor Conference that is being held on Wednesday, December 11, 2024, at the New York Athletic Club in New York City.
See all news
